Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme

Marjan van Blerk, Els Bailleul, B Chatelain, Anne Demulder, Katrien Devreese, J Douxfils, M Jacquemin, K Jochmans, F Mullier, Walter Wijns, B China, K Vernelen, M R Soumali

Résultats de recherche: Contribution à un journal/une revueArticle

Résumé

INTRODUCTION: The Belgian national External Quality Assessment Scheme performed a survey to assess the effect of the direct oral anticoagulant apixaban on the coagulation assays prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and antithrombin as performed with a large number of reagent/instrument combinations.

METHODS: Four lyophilized plasma samples spiked with apixaban (0, 41, 94 and 225 ng/mL) were sent to the 195 Belgian and Luxembourg clinical laboratories performing coagulation testing.

RESULTS: PT and aPTT were barely influenced at the concentrations tested. At 225 ng/mL apixaban, PT and aPTT clotting times were only 1.15 times longer than at 0 ng/mL. Among PT reagents, RecombiPlasTin 2G(®) showed a slightly higher sensitivity with 225 ng/mL apixaban prolonging the PT clotting time 1.3-fold. Among aPTT reagents, there was no appreciable difference in sensitivity. Fibrinogen results were unaffected by the presence of apixaban, but antithrombin activity was considerably overestimated when measured with a FXa-based assay. At 225 ng/mL apixaban, the median percentage increase in antithrombin level was 31% when measured with the Liquid Antithrombin(®) reagent and 44% with the Innovance Antithrombin(®) reagent.

CONCLUSION: Our data provide clinical laboratories with useful information on the impact of apixaban on their routine coagulation assays.

langueAnglais
journalInternational Journal of Laboratory Hematology
Les DOIs
étatE-pub ahead of print - 2017
Modification externeOui

Empreinte digitale

Coagulation
Assays
Antithrombins
Prothrombin Time
Prothrombin
Partial Thromboplastin Time
Thromboplastin
Clinical laboratories
Fibrinogen
Luxembourg
apixaban
Anticoagulants
Plasmas
Liquids
Testing

mots-clés

    Citer ceci

    van Blerk, Marjan ; Bailleul, Els ; Chatelain, B ; Demulder, Anne ; Devreese, Katrien ; Douxfils, J ; Jacquemin, M ; Jochmans, K ; Mullier, F ; Wijns, Walter ; China, B ; Vernelen, K ; Soumali, M R. / Influence of apixaban on commonly used coagulation assays : results from the Belgian national External Quality Assessment Scheme. Dans: International Journal of Laboratory Hematology. 2017
    @article{23356b03f04b4d7686ed3fd13e5b40f8,
    title = "Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme",
    abstract = "INTRODUCTION: The Belgian national External Quality Assessment Scheme performed a survey to assess the effect of the direct oral anticoagulant apixaban on the coagulation assays prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and antithrombin as performed with a large number of reagent/instrument combinations.METHODS: Four lyophilized plasma samples spiked with apixaban (0, 41, 94 and 225 ng/mL) were sent to the 195 Belgian and Luxembourg clinical laboratories performing coagulation testing.RESULTS: PT and aPTT were barely influenced at the concentrations tested. At 225 ng/mL apixaban, PT and aPTT clotting times were only 1.15 times longer than at 0 ng/mL. Among PT reagents, RecombiPlasTin 2G({\circledR}) showed a slightly higher sensitivity with 225 ng/mL apixaban prolonging the PT clotting time 1.3-fold. Among aPTT reagents, there was no appreciable difference in sensitivity. Fibrinogen results were unaffected by the presence of apixaban, but antithrombin activity was considerably overestimated when measured with a FXa-based assay. At 225 ng/mL apixaban, the median percentage increase in antithrombin level was 31{\%} when measured with the Liquid Antithrombin({\circledR}) reagent and 44{\%} with the Innovance Antithrombin({\circledR}) reagent.CONCLUSION: Our data provide clinical laboratories with useful information on the impact of apixaban on their routine coagulation assays.",
    keywords = "Journal Article",
    author = "{van Blerk}, Marjan and Els Bailleul and B Chatelain and Anne Demulder and Katrien Devreese and J Douxfils and M Jacquemin and K Jochmans and F Mullier and Walter Wijns and B China and K Vernelen and Soumali, {M R}",
    note = "{\circledC} 2017 John Wiley & Sons Ltd.",
    year = "2017",
    doi = "10.1111/ijlh.12640",
    language = "English",
    journal = "International Journal of Laboratory Hematology",
    issn = "1751-553X",
    publisher = "Wiley-Blackwell Publishing",

    }

    Influence of apixaban on commonly used coagulation assays : results from the Belgian national External Quality Assessment Scheme. / van Blerk, Marjan; Bailleul, Els; Chatelain, B; Demulder, Anne; Devreese, Katrien; Douxfils, J; Jacquemin, M; Jochmans, K; Mullier, F; Wijns, Walter; China, B; Vernelen, K; Soumali, M R.

    Dans: International Journal of Laboratory Hematology, 2017.

    Résultats de recherche: Contribution à un journal/une revueArticle

    TY - JOUR

    T1 - Influence of apixaban on commonly used coagulation assays

    T2 - International Journal of Laboratory Hematology

    AU - van Blerk,Marjan

    AU - Bailleul,Els

    AU - Chatelain,B

    AU - Demulder,Anne

    AU - Devreese,Katrien

    AU - Douxfils,J

    AU - Jacquemin,M

    AU - Jochmans,K

    AU - Mullier,F

    AU - Wijns,Walter

    AU - China,B

    AU - Vernelen,K

    AU - Soumali,M R

    N1 - © 2017 John Wiley & Sons Ltd.

    PY - 2017

    Y1 - 2017

    N2 - INTRODUCTION: The Belgian national External Quality Assessment Scheme performed a survey to assess the effect of the direct oral anticoagulant apixaban on the coagulation assays prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and antithrombin as performed with a large number of reagent/instrument combinations.METHODS: Four lyophilized plasma samples spiked with apixaban (0, 41, 94 and 225 ng/mL) were sent to the 195 Belgian and Luxembourg clinical laboratories performing coagulation testing.RESULTS: PT and aPTT were barely influenced at the concentrations tested. At 225 ng/mL apixaban, PT and aPTT clotting times were only 1.15 times longer than at 0 ng/mL. Among PT reagents, RecombiPlasTin 2G(®) showed a slightly higher sensitivity with 225 ng/mL apixaban prolonging the PT clotting time 1.3-fold. Among aPTT reagents, there was no appreciable difference in sensitivity. Fibrinogen results were unaffected by the presence of apixaban, but antithrombin activity was considerably overestimated when measured with a FXa-based assay. At 225 ng/mL apixaban, the median percentage increase in antithrombin level was 31% when measured with the Liquid Antithrombin(®) reagent and 44% with the Innovance Antithrombin(®) reagent.CONCLUSION: Our data provide clinical laboratories with useful information on the impact of apixaban on their routine coagulation assays.

    AB - INTRODUCTION: The Belgian national External Quality Assessment Scheme performed a survey to assess the effect of the direct oral anticoagulant apixaban on the coagulation assays prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and antithrombin as performed with a large number of reagent/instrument combinations.METHODS: Four lyophilized plasma samples spiked with apixaban (0, 41, 94 and 225 ng/mL) were sent to the 195 Belgian and Luxembourg clinical laboratories performing coagulation testing.RESULTS: PT and aPTT were barely influenced at the concentrations tested. At 225 ng/mL apixaban, PT and aPTT clotting times were only 1.15 times longer than at 0 ng/mL. Among PT reagents, RecombiPlasTin 2G(®) showed a slightly higher sensitivity with 225 ng/mL apixaban prolonging the PT clotting time 1.3-fold. Among aPTT reagents, there was no appreciable difference in sensitivity. Fibrinogen results were unaffected by the presence of apixaban, but antithrombin activity was considerably overestimated when measured with a FXa-based assay. At 225 ng/mL apixaban, the median percentage increase in antithrombin level was 31% when measured with the Liquid Antithrombin(®) reagent and 44% with the Innovance Antithrombin(®) reagent.CONCLUSION: Our data provide clinical laboratories with useful information on the impact of apixaban on their routine coagulation assays.

    KW - Journal Article

    U2 - 10.1111/ijlh.12640

    DO - 10.1111/ijlh.12640

    M3 - Article

    JO - International Journal of Laboratory Hematology

    JF - International Journal of Laboratory Hematology

    SN - 1751-553X

    ER -